[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100120414":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":44,"centralContacts":10,"locations":49,"responsibleParty":63,"collaborators":10,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":78,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":10,"overallStatus":84,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Genentech, Inc.","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants Treated With Trastuzumab",null,"Participants who are being treated with trastuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.",[13],"Drug: Trastuzumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Participants Treated With Trastuzumab and Pertuzumab","Participants who are being treated with the combination of trastuzumab and pertuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.",[13,18],"Drug: Pertuzumab",{"label":20,"type":10,"description":21,"interventionNames":22},"Participants Treated With Ado-Trastuzumab Emtansine","Participants who are being treated with ado-trastuzumab emtansine during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.",[23],"Drug: Ado-Trastuzumab Emtansine",[25,32,38],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Trastuzumab","Participants will receive trastuzumab as determined by their treating physicians' standards of care.",[9,15],[31],"Herceptin",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Pertuzumab","Participants will receive pertuzumab as determined by their treating physicians' standards of care.",[15],[37],"Perjeta",{"type":26,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Ado-Trastuzumab Emtansine","Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.",[20],[43],"Kadcyla",[45],{"name":46,"affiliation":47,"role":48},"Vikki Brown, M.D.","Syneos Health","STUDY_DIRECTOR",[50],{"facility":51,"status":10,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":10},"Kendle International, Inc","Wilmington","North Carolina","28405","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-77.94604,34.23556,{"lat":61,"lon":60},{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100120414","a-study-of-pregnancy-and-pregnancy-outcomes-in-women-with-breast-cancer-treated-with-trastuzumab-pertuzumab-in-combination-with-trastuzumab-or-ado-trastuzumab-emtansine-100120414",false,"NCT00833963","A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine","An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception","MotHER","Inclusion Criteria:\n\n* Pregnant; women identified at any trimester of pregnancy may enroll in this study as long as enrollment occurs prior to experiencing pregnancy outcome (that is \\[i.e.\\], live birth, stillbirth, or abortion)\n* Exposure to at least one dose of trastuzumab (as adjuvant or metastatic treatment), pertuzumab plus trastuzumab combination treatment, or ado-trastuzumab emtansine during pregnancy or within 7 months prior to conception\n* United States resident\n\nExclusion Criteria:\n\n* Prior knowledge of pregnancy outcome (i.e., live birth, stillbirth, or abortion) at time of enrollment","FEMALE","18 Years",{"count":76,"type":77},20,"ACTUAL","12 Months","OBSERVATIONAL","The MotHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or ado-trastuzumab emtansine (kadcyla) during pregnancy or within 7 months prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab emtansine exposure).",[82,83],"Breast Cancer","Pregnancy","COMPLETED","2019-05-15",{"date":87,"type":77},"2019-05-16",{"date":89,"type":77},"2009-01-14",{"date":91,"type":77},"2017-04-13",{"name":5,"class":6},1]